PTD-DBM

PTD-DBM is a synthetic peptide combining a protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) derived from the CXXC5 protein, engineered to penetrate cells and disrupt the CXXC5-Dishevelled protein-protein interaction that normally suppresses Wnt/beta-catenin signaling, with the goal of reactivating the Wnt pathway in hair follicle stem cells to promote follicle cycling and hair regrowth in androgenetic alopecia. The proposed mechanism targets a specific negative regulatory checkpoint: CXXC5 binds Dishevelled to prevent beta-catenin nuclear translocation; the PTD-DBM peptide competitively disrupts this interaction to restore Wnt pathway activity in follicular dermal papilla cells, a mechanism demonstrated to stimulate hair follicle activation in preclinical mouse models of hair loss.

hair regeneration, hair follicle activation, Wnt pathway modulation, follicle neogenesis.

Research on PTD-DBM primarily documents effects related to hair regeneration and hair follicle activation and Wnt pathway modulation and follicle neogenesis. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For PTD-DBM, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

6 providers in the directory currently offer PTD-DBM.

PTD-DBM is tracked across 1 research vendor on PeptideBase, at about $16.40 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.